Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia
about
Main roads to melanomaRaf family kinases: old dogs have learned new tricksRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceGenetic signature of histiocytic sarcoma revealed by a sleeping beauty transposon genetic screen in miceRaf kinases in cancer-roles and therapeutic opportunitiesRheb inhibits C-raf activity and B-raf/C-raf heterodimerizationTherapy-related myeloid neoplasms: pathobiology and clinical characteristicsMAP kinase signalling pathways in cancerRAF and antioxidants prevent cell death induction after growth factor abrogation through regulation of Bcl-2 proteins.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Raf kinases: function, regulation and role in human cancer.Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.Raf kinases: oncogenesis and drug discovery.Constitutive activation of Raf-1 induces glioma formation in mice.BRAF(E600) in benign and malignant human tumours.CRAF R391W is a melanoma driver oncogeneSelective Raf inhibition in cancer therapy.Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality.Emerging Raf inhibitors.Emerging MEK inhibitors.Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.C-RAF mutations confer resistance to RAF inhibitors.Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia.Tyr phosphatase-mediated P-ERK inhibition suppresses senescence in EIA + v-raf transformed cells, which, paradoxically, are apoptosis-protected in a MEK-dependent mannerTargeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia.Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization.Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability?
P2860
Q21245465-EE1B3186-F468-41B8-8F47-0138B93569CAQ24316181-C805A121-5640-4557-B856-075FF100D152Q24645668-90629BA5-B077-4066-9B02-E4DE4425BBC1Q27332453-BE2F8A02-CC5E-456C-9271-F542591D3E77Q28237793-EFD6D499-BA27-40A1-98DA-19EEDA2B314AQ28248759-B1AF639E-1F4B-4B83-B41F-4788236E6F21Q28386366-CA8C252B-B458-426A-BBA1-968C391C31F5Q29615542-594FF9FC-DD0E-49BF-92D1-E55FC4773AE5Q34915160-7F87968B-F010-4FE5-8433-D5D16D647326Q34966603-FC84C36E-45D0-47B6-97C8-0CF1312C3490Q36002845-A349DD42-767A-4019-8F39-0C0FB8029061Q36022862-669B1218-1622-4E0D-A3D4-F6E68E81613BQ36559414-7AAE7F36-161C-4C92-B20B-14ACD6D24D96Q36640215-33564686-4767-482C-B11E-51A1552C4105Q36921234-9B68B55A-FA81-4C76-B199-4FC97F3DDB75Q36980239-9601BA08-70BA-4502-BB24-C97EEDCA6B37Q37004743-C98D76C0-4BD9-457C-83A3-34E861178CDAQ37109227-BD028D54-D143-41F7-ACF6-3A1AD4074AAAQ37389958-80D2D927-E59A-40C7-8112-654C832364EFQ37560138-C3C427AF-5E75-4ED4-88B1-5B0B70F8DB06Q37588717-329099AC-072B-4EF7-AB37-F09D93F17387Q37691441-9B827F1E-C572-45B4-B1CA-5530102255DFQ37822317-11157382-146C-442A-907A-0C7A13517DDCQ37865381-41EB41C3-37BB-4F7A-AAA1-9A93EB280371Q39143850-94729AE2-7823-435F-8104-3E9E0A38EAF3Q39386021-C527E2CE-9312-4BB2-A6A8-6EC9C0B3D7BAQ39576124-B0829A4F-311A-40E4-8173-141F4F27253DQ40154931-4FA77696-1AE6-4C95-8772-146BDF096BCFQ42394768-6CE0F034-B70C-4D73-BE4D-9B93FC827E5BQ42683550-30F6A599-8A5D-4EE6-ABD8-C6DBBC88384EQ49359653-589DF10C-30D5-41F0-B9E0-AC659A194395Q52739043-E7C016F6-13C5-4965-9930-BC03DF8117A2Q54449164-4E335A3B-7102-437B-A8DB-A82BD894C677
P2860
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@ast
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@en
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@nl
type
label
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@ast
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@en
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@nl
prefLabel
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@ast
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@en
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@nl
P2093
P50
P3181
P1433
P1476
Two transforming C-RAF germ-li ...... related acute myeloid leukemia
@en
P2093
Ali Delavar
Christian Windpassinger
Claudia Bodner
Jakob Troppmair
Karin Hiden
Katja Fischereder
Manickam Janakiraman
Michael G Schimek
Philipp B Staber
Werner Emberger
P304
P3181
P356
10.1158/0008-5472.CAN-05-0115
P407
P577
2006-04-01T00:00:00Z